2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2102

Higher Persistence and Adherence with Combination Therapy with Tumor Necrosis Factor Inhibitor+Methotrexate Combination Versus Triple Therapy in US Veterans with Rheumatoid Arthritis
Abstract Number: 26

Higher Scores of Women Compared to Men for Most Clinical Measures of Rheumatoid Arthritis (RA) Status: Greater Differences for Patient Self-Report Scores Than for Rheumatologist Estimates: A Cross-Sectional 3 Center Study from Routine Care
Abstract Number: 2811

Higher Serum Level of Leptin Protects from Radiographic Spinal Progression in Patients with Ankylosing Spondylitis
Abstract Number: 242

Higher Serum Uric Acid Levels Are Associated with an Increased Risk of Flares: A Systematic Review
Abstract Number: 2114

Higher Total Knee Arthroplasty Revision Rates in Black Americans: A Systematic Literature Review and Meta-Analysis
Abstract Number: 453

Highly Elevated Rheumatoid Factor Is a Risk Factor for Abatacept Treatment Failure in Japanese Patients with Rheumatoid Arthritis
Abstract Number: 2472

Highly Elevated S100A8/A9 and S100A12 Levels May Distinguish Systemic Juvenile Idiopathic Arthritis Patients with New Onset Disease and Subclinical Macrophage Activation Syndrome
Abstract Number: 2391

Hip Osteoarthritis As the Cause for Knee Osteoarthritis in the Multicenter Osteoarthritis Study
Abstract Number: 510

Histologic Scoring of Arthroplasty Synovial Samples May Predict RA Flare
Abstract Number: 3132

Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis Via Repressing Pro-Angiogenic Factors
Abstract Number: 3080

Histone H2AX Phosphorylation As a Measure of DNA Double Strand Breaks and a Marker of Environmental Stress and Disease Activity in Lupus
Abstract Number: 204

Histone Methylation Profiling in Peripheral White Blood Cells As a Candidate Biomarker for Behcet’s Disease
Abstract Number: 2101

HLA Associations in Mothers of Children with Cardiac Manifestations of Neonatal Lupus
Abstract Number: 3035

HLA B51 and Possible Associated Autoimmune Disorders Other Than Behcets Disease: A Retrospective Cohort Study
Abstract Number: 979

HLA Class I Genes As Susceptibility Markers of Psoriatic Arthritis in Patients with Psoriasis – a Meta-Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].